Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.02, Bloomberg Earnings reports.

Marinus Pharmaceuticals (NASDAQ:MRNS) traded up 1.08% during trading on Wednesday, hitting $5.60. The company had a trading volume of 203,054 shares. Marinus Pharmaceuticals has a one year low of $0.82 and a one year high of $8.22. The company’s market capitalization is $146.02 million. The stock has a 50-day moving average of $5.39 and a 200 day moving average of $2.70.

TRADEMARK VIOLATION WARNING: “Marinus Pharmaceuticals, Inc. (MRNS) Releases Earnings Results” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at

A number of analysts have commented on the company. ValuEngine upgraded Marinus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 25th. JMP Securities reiterated an “outperform” rating and issued a $11.00 price objective (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 12th.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Earnings History for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.